SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-076164
Filing Date
2022-03-15
Accepted
2022-03-15 16:40:05
Documents
14
Period of Report
2022-03-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d333137d8k.htm   iXBRL 8-K 25244
2 EX-99.1 d333137dex991.htm EX-99.1 55394
6 GRAPHIC g333137page5a.jpg GRAPHIC 4694
  Complete submission text file 0001193125-22-076164.txt   222529

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA stsa-20220315.xsd EX-101.SCH 2863
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE stsa-20220315_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stsa-20220315_pre.xml EX-101.PRE 11712
8 EXTRACTED XBRL INSTANCE DOCUMENT d333137d8k_htm.xml XML 3465
Mailing Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080
Business Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080 415-505-0809
Satsuma Pharmaceuticals, Inc. (Filer) CIK: 0001692830 (see all company filings)

IRS No.: 813039831 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39041 | Film No.: 22741712
SIC: 2834 Pharmaceutical Preparations